Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 33: EUROPA-Studie - Charakteristika Abb. 34: EUROPA-Studie - Anamnese Abb. 35: EUROPA-Studie - Risikofaktoren Aktuelles Bild - Abb. 36: EUROPA-Studie - Medikation Abb. 37: EUROPA-Studie - Resultate Abb. 38: EUROPA-Studie - Primärer Endpunkt Abb. 39: EUROPA-Studie - Endpunkte Zum letzten Bild
Abbildung 36: EUROPA-Studie - Medikation
Of particular importance when it comes to interpretation of this study is the background treatment. Demographic data clearly demonstrate that the EUROPA patients were receiving perindopril or placebo on top of optimal preventive therapy. Most of the randomised coronary artery disease patients were treated with platelet inhibitors, B-blockers, lipid lowering drugs, nitrates, Ca-blockers, diuretics and oral anticoagulants. Homogeneity was maintained between these two groups of patients.
 
EUROPA-Studie - Medikation
Vorheriges Bild Nächstes Bild   


Abbildung 36: EUROPA-Studie - Medikation
Of particular importance when it comes to interpretation of this study is the background treatment. Demographic data clearly demonstrate that the EUROPA patients were receiving perindopril or placebo on top of optimal preventive therapy. Most of the randomised coronary artery disease patients were treated with platelet inhibitors, B-blockers, lipid lowering drugs, nitrates, Ca-blockers, diuretics and oral anticoagulants. Homogeneity was maintained between these two groups of patients.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung